397 related articles for article (PubMed ID: 31635468)
1. Non-Alcoholic Fatty Liver Disease.
Brůha R
Vnitr Lek; 2019; 65(9):571-575. PubMed ID: 31635468
[TBL] [Abstract][Full Text] [Related]
2. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.
Long MT; Noureddin M; Lim JK
Gastroenterology; 2022 Sep; 163(3):764-774.e1. PubMed ID: 35842345
[TBL] [Abstract][Full Text] [Related]
3. Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study.
Simon TG; Roelstraete B; Hagström H; Loomba R; Ludvigsson JF
J Hepatol; 2023 Dec; 79(6):1366-1373. PubMed ID: 37604268
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers.
Basu R; Noureddin M; Clark JM
Mayo Clin Proc; 2022 Sep; 97(9):1700-1716. PubMed ID: 36058582
[TBL] [Abstract][Full Text] [Related]
5. The roles of type 2 diabetes and obesity in disease activity and progression of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
Shinde S; Nelson DR; Mitroi J; Heaton PC; Hincapie AL; Brouwers B
Curr Med Res Opin; 2024 Jan; 40(1):59-68. PubMed ID: 37933187
[TBL] [Abstract][Full Text] [Related]
6. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis.
Leoni S; Tovoli F; Napoli L; Serio I; Ferri S; Bolondi L
World J Gastroenterol; 2018 Aug; 24(30):3361-3373. PubMed ID: 30122876
[TBL] [Abstract][Full Text] [Related]
7. Non-Alcoholic Fatty Liver Disease in Obese Youth With Insulin Resistance and Type 2 Diabetes.
Scapaticci S; D'Adamo E; Mohn A; Chiarelli F; Giannini C
Front Endocrinol (Lausanne); 2021; 12():639548. PubMed ID: 33889132
[TBL] [Abstract][Full Text] [Related]
8. Non-alcoholic fatty liver disease.
Maurice J; Manousou P
Clin Med (Lond); 2018 Jun; 18(3):245-250. PubMed ID: 29858436
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine.
Noureddin M; Mato JM; Lu SC
Exp Biol Med (Maywood); 2015 Jun; 240(6):809-20. PubMed ID: 25873078
[TBL] [Abstract][Full Text] [Related]
10. Current status, problems, and perspectives of non-alcoholic fatty liver disease research.
Tanaka N; Kimura T; Fujimori N; Nagaya T; Komatsu M; Tanaka E
World J Gastroenterol; 2019 Jan; 25(2):163-177. PubMed ID: 30670907
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options.
Milic S; Mikolasevic I; Krznaric-Zrnic I; Stanic M; Poropat G; Stimac D; Vlahovic-Palcevski V; Orlic L
Drug Des Devel Ther; 2015; 9():4835-45. PubMed ID: 26316717
[TBL] [Abstract][Full Text] [Related]
12. Anti-osteoporotic treatments in the era of non-alcoholic fatty liver disease: friend or foe.
Chondrogianni ME; Kyrou I; Androutsakos T; Flessa CM; Menenakos E; Chatha KK; Aranan Y; Papavassiliou AG; Kassi E; Randeva HS
Front Endocrinol (Lausanne); 2024; 15():1344376. PubMed ID: 38524631
[TBL] [Abstract][Full Text] [Related]
13. Advanced fibrosis associated with non-alcoholic steatohepatitis (NASH) in Spain: results of a Delphi study.
Aller R; Calleja JL; Crespo J; Romero-Gómez M; Turnes J; Benmarzouk-Hidalgo OJ; Subirán R; Gil A
Gastroenterol Hepatol; 2024 Apr; 47(4):337-346. PubMed ID: 37343722
[TBL] [Abstract][Full Text] [Related]
14. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice.
Dulai PS; Sirlin CB; Loomba R
J Hepatol; 2016 Nov; 65(5):1006-1016. PubMed ID: 27312947
[TBL] [Abstract][Full Text] [Related]
15. [Non-alcoholic fatty liver disease: aspects of management of a comorbid patient. A review].
Demidova TY; Ushanova FO
Ter Arkh; 2023 Nov; 95(10):888-895. PubMed ID: 38159023
[TBL] [Abstract][Full Text] [Related]
16. Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment.
Sangro P; de la Torre Aláez M; Sangro B; D'Avola D
J Physiol Biochem; 2023 Nov; 79(4):869-879. PubMed ID: 36976456
[TBL] [Abstract][Full Text] [Related]
17. Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products.
Fernando DH; Forbes JM; Angus PW; Herath CB
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614491
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic fatty liver disease.
Li W; Alazawi W
Clin Med (Lond); 2020 Sep; 20(5):509-512. PubMed ID: 32934047
[TBL] [Abstract][Full Text] [Related]
19. [Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)].
Canivet CM; Faure S
Rev Med Interne; 2024 Jan; 45(1):41-47. PubMed ID: 38158295
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
